Clinical Trial

A Phase 1, First in Human Study of TORL-4-500 in Patients With Advanced Cancer

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated March 4, 2025 (before its estimated October 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-4-500 in patients with advanced cancer. For Part 1, any advanced or metastatic solid tumor malignancy will be evaluated including, for example, adrenocortical carcinoma (ACC).
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2023-08-15; most recent amendment 2025-02-27.
Status change: Not Yet Recruiting → Recruiting 2023-12-21
Trial Details
NCT Number NCT06005740
Lead Sponsor TORL Biotherapeutics, LLC
Collaborators: Translational Research in Oncology
Conditions Advanced Solid Tumor, Hepatocellular Carcinoma
Enrollment 70 participants
Start Date 2023-12-04
Primary Completion 2025-10-31 (estimated)
Study Completion 2026-10-31 (estimated)
Updated on ClinicalTrials.gov 2025-03-04